KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Shares Outstanding for 13 consecutive years, with $80.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 4.7% to $80.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $80.0 million, a 4.7% increase, with the full-year FY2025 number at $80.0 million, up 4.7% from a year prior.
  • Shares Outstanding was $80.0 million for Q4 2025 at Xenon Pharmaceuticals, up from $77.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $80.0 million in Q4 2025 to a low of $1.0 million in Q1 2021.
  • A 5-year average of $60.3 million and a median of $64.4 million in 2023 define the central range for Shares Outstanding.
  • Biggest YoY gain for Shares Outstanding was 4982.16% in 2021; the steepest drop was 97.1% in 2021.
  • Xenon Pharmaceuticals' Shares Outstanding stood at $51.6 million in 2021, then rose by 21.21% to $62.6 million in 2022, then rose by 20.42% to $75.4 million in 2023, then grew by 1.39% to $76.4 million in 2024, then increased by 4.7% to $80.0 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Shares Outstanding are $80.0 million (Q4 2025), $77.1 million (Q3 2025), and $76.9 million (Q2 2025).